BACKGROUND: Little is known about the effects of statins on the quality of circulating low-density lipoprotein (LDL) in relation to atherosclerosis progression. METHODS: In a double-blind, randomized trial of 325 patients with familial hypercholesterolemia (FH), we assessed the effects of high-dose atorvastatin (80 mg) and conventional-dose simvastatin (40 mg) on LDL subfraction profile (n = 289), LDL oxidizability (n = 121), and circulating autoantibodies to oxidized LDL (n = 220). Progression of atherosclerosis was measured by carotid intima media thickness (IMT) (n = 325). RESULTS: At baseline, the patients showed an intermediate LDL subfraction profile composed of three LDL subfractions (LDL1, LDL2, LDL3), with LDL2 as the predominant s...
Background: Atorvastatin reduces oxidized low-density lipoprotein (oxLDL) levels and reduces the rat...
Test whether angiographically-documented changes in percent stenosis and clinical endpoints (coronar...
Test whether angiographically-documented changes in percent stenosis and clinical endpoints (coronar...
Item does not contain fulltextBACKGROUND: Little is known about the effects of statins on the qualit...
OBJECTIVE: Circulating oxidized low-density lipoprotein (LDL) has been shown to be a useful marker f...
BACKGROUND: High LDL-cholesterol is a risk factor for atherosclerosis. We aimed to determine whether...
Objective: It is unclear at the present time whether hydroxy-methylglutaryl coenzyme A reductase inh...
BACKGROUND: Raised plasma lipoprotein(a) (Lp(a)) is associated with increased risk of cardiovascular...
BACKGROUND: Ezetimibe, a cholesterol-absorption inhibitor, reduces levels of low-density lipoprotein...
Elevation of plasma cholesterol and/or triglycerides, and the prevalence of small dense low density ...
Background: Ezetimibe, a cholesterol-absorption inhibitor, reduces levels of low-density lipoprotein...
Background: Elevated plasma low-density lipoprotein cholesterol (LDL-C) is the main risk factor for ...
BACKGROUND: Cardiovascular disease as a result of accelerated atherogenesis is common in patients wi...
<p><strong>BACKGROUND:</strong> The major aim of this study was evaluating the effect of atorvastati...
Background:Despite the reduction in cholesterol (CH) levels, the modification of carotid intima–medi...
Background: Atorvastatin reduces oxidized low-density lipoprotein (oxLDL) levels and reduces the rat...
Test whether angiographically-documented changes in percent stenosis and clinical endpoints (coronar...
Test whether angiographically-documented changes in percent stenosis and clinical endpoints (coronar...
Item does not contain fulltextBACKGROUND: Little is known about the effects of statins on the qualit...
OBJECTIVE: Circulating oxidized low-density lipoprotein (LDL) has been shown to be a useful marker f...
BACKGROUND: High LDL-cholesterol is a risk factor for atherosclerosis. We aimed to determine whether...
Objective: It is unclear at the present time whether hydroxy-methylglutaryl coenzyme A reductase inh...
BACKGROUND: Raised plasma lipoprotein(a) (Lp(a)) is associated with increased risk of cardiovascular...
BACKGROUND: Ezetimibe, a cholesterol-absorption inhibitor, reduces levels of low-density lipoprotein...
Elevation of plasma cholesterol and/or triglycerides, and the prevalence of small dense low density ...
Background: Ezetimibe, a cholesterol-absorption inhibitor, reduces levels of low-density lipoprotein...
Background: Elevated plasma low-density lipoprotein cholesterol (LDL-C) is the main risk factor for ...
BACKGROUND: Cardiovascular disease as a result of accelerated atherogenesis is common in patients wi...
<p><strong>BACKGROUND:</strong> The major aim of this study was evaluating the effect of atorvastati...
Background:Despite the reduction in cholesterol (CH) levels, the modification of carotid intima–medi...
Background: Atorvastatin reduces oxidized low-density lipoprotein (oxLDL) levels and reduces the rat...
Test whether angiographically-documented changes in percent stenosis and clinical endpoints (coronar...
Test whether angiographically-documented changes in percent stenosis and clinical endpoints (coronar...